Drug firm Lupin said on Wednesday that it has received final approval from the US health regulator for its generic Amabelz tablets, used for severe vasomotor in the American market.
As many as 2,839 bottles of anti-bacterial medicine Nitrofurantoin Oral Suspension manufactured by Sun Pharmaceutical Industries are being recalled in the US market on account of failed dissolution specifications. The ongoing voluntary recall by Nostrum Laboratories Inc. for Nitrofurantoin Oral Suspension, USP, 25 mg/5 mL is a class II recall, according to the latest enforcement report on USFDA site.
Drug firm Lupin said on Wednesday that it has received final approval from the US health regulator for its generic Amabelz tablets, used for severe vasomotor in the American market.
The central government is revising its drugs law to make it easier for companies to do business while ensuring the safety and efficacy of medicines, in Prime Minister Narendra Modi’s latest move to encourage industry. Until last year, India was trying to tweak its archaic Drugs and Cosmetics Act of 1940, and an amendment bill was introduced in the upper house of parliament in 2013.
In ratings reviews that it published on Wednesday, credit rating agency ICRA downgraded the long-term rating of Deepak Fertilizers while placing that of Fortis Healthcare on watch. For Deepak Fertilizers and Petrochemicals Corporation, ICRA revised the long-term rating assigned to the Rs 600-crore non-convertible debenture programme, Rs 575-crore (increased from Rs 500 crore) long-term fund-based limits and Rs 141.44-crore term loans from AA to AA-, the agency said in a note.
Home-grown private equity fund ChrysCapital is in initial talks with private equity funds Apax Parters, Advent International, Multiples Alternatives, Barings Asia and Carlyle to sell its 16% stake in Ahmedabad-based Eris Lifesciences. The drugmaker is being valued at $400-450 million, said three people with direct knowledge of the discussions for a proposed transaction. In 2011, ChrysCap picked up 16% stake in Eris Lifesciences for .Rs 160 crore.
The government’s decision to allow foreign direct investment (FDI) up to 74% through automatic route in existing pharmaceutical companies is likely to hit affordable healthcare in the country, especially in the vaccine (in which the government also runs programmes) and injectables segments, according to senior domestic indust ry execu tives. Vaccines and injectables are ch allenging vert icals wit h very few good manufacturing facilities in India and even fewer firms invest in research and development in these verticals.
Drug firm Lupin said on Wednesday that it has received final approval from the US health regulator for its generic Amabelz tablets, used for severe vasomotor in the American market.
The central government is revising its drugs law to make it easier for companies to do business while ensuring the safety and efficacy of medicines, in Prime Minister Narendra Modi’s latest move to encourage industry. Until last year, India was trying to tweak its archaic Drugs and Cosmetics Act of 1940, and an amendment bill was introduced in the upper house of parliament in 2013.
In ratings reviews that it published on Wednesday, credit rating agency ICRA downgraded the long-term rating of Deepak Fertilizers while placing that of Fortis Healthcare on watch. For Deepak Fertilizers and Petrochemicals Corporation, ICRA revised the long-term rating assigned to the Rs 600-crore non-convertible debenture programme, Rs 575-crore (increased from Rs 500 crore) long-term fund-based limits and Rs 141.44-crore term loans from AA to AA-, the agency said in a note.
Home-grown private equity fund ChrysCapital is in initial talks with private equity funds Apax Parters, Advent International, Multiples Alternatives, Barings Asia and Carlyle to sell its 16% stake in Ahmedabad-based Eris Lifesciences. The drugmaker is being valued at $400-450 million, said three people with direct knowledge of the discussions for a proposed transaction. In 2011, ChrysCap picked up 16% stake in Eris Lifesciences for .Rs 160 crore.
The government’s decision to allow foreign direct investment (FDI) up to 74% through automatic route in existing pharmaceutical companies is likely to hit affordable healthcare in the country, especially in the vaccine (in which the government also runs programmes) and injectables segments, according to senior domestic indust ry execu tives. Vaccines and injectables are ch allenging vert icals wit h very few good manufacturing facilities in India and even fewer firms invest in research and development in these verticals.
No comments:
Post a Comment